Dermorphin decreases plasma LH levels in human: evidence for a modulatory role of gonadal steroids.
The purpose of this study was to evaluate the effects of dermorphin, a new synthetic powerful opiate-like heptapeptide, on plasma luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in fertile and postmenopausal women. In fertile subjects, dermorphin (5.5 micrograms/kg min for 30 min) decreases plasma LH (p less than 0.01 vs. baseline and placebo values), but not plasma FSH. The area under the curve during dermorphin infusion was significantly lower than during placebo infusion (p less than 0.01). Pretreatment with the opioid receptor antagonist naloxone, blocked the decrease of plasma LH levels. In postmenopausal women not subjected to any treatment, dermorphin infusion did not significantly modify plasma LH and FSH levels. On the contrary, its administration to postmenopausal subjects treated with conjugated estrogens and medroxyprogesterone acetate significantly decreased plasma LH levels (p less than 0.01, vs. baseline, placebo and area under the curve). Considering the modulatory role exerted by ovarian steroids on the activity of such receptors, these data also indicate that opioid systems play a very important part in the hypothalamus-pituitary-ovarian axis.
D000328:Adult; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D012739:Gonadal Steroid Hormones / Q000502:physiology*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008593:Menopause; D008875:Middle Aged; D009842:Oligopeptides / Q000494:pharmacology*; D018847:Opioid Peptides
D012739:Gonadal Steroid Hormones; D009842:Oligopeptides; D018847:Opioid Peptides; C030058:dermorphin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone